NEW ORLEANS, May 20, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported a stabilization of disease, as measured by computed tomography (CT) according to RECIST criteria, in pancreatic cancer patients with advanced disease and who failed 1-5 prior therapies. In a group of 13 CT-assessable patients receiving repeated doses of the Company's investigational antibody-drug conjugate (ADC), IMMU-132, a median time-to-progression of 12.7 weeks was reported (range 4.3-21.4 weeks), which is better than the median 8.0 weeks (range 4-36 weeks) estimated from their last prior therapy.
Results from the ongoing Phase I/II study were presented at the American Association for Cancer Research Special Conference on Pancreatic Cancer: Innovations in Research and Treatment by Vincent J. Picozzi Jr., M.D., Director of the Pancreas Center of Excellence at the Virginia Mason Medical Center's Digestive Disease Institute, Seattle, WA.
It is known that in such advanced, highly malignant cancers, responses and outcome are poorer with each successive treatment. "This is why we are encouraged that this group of heavily pretreated, advanced pancreatic cancer patients showed a longer period of disease control compared with their most recent therapy before entering this trial," Dr. Picozzi stated.A total of 15 advanced PDC patients who relapsed after a median of 2 prior therapies (range 1-5) have been enrolled in the multicenter trial. One patient was not evaluated due to clinical progression, while another patient's CT assessment is pending. Patients were administered IMMU-132 on days 1 and 8 in repeated 21-day cycles for up to 8 cycles. IMMU-132 consists of the Company's proprietary anti-TROP-2 humanized antibody conjugated with a high number of SN-38 drug molecules by a site-specific linker technology. Preclinical studies have indicated that a significantly higher amount of SN-38, the active metabolite of irinotecan, is delivered to human cancers growing in mice than when high doses of the parent compound, irinotecan, is given.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts